Journals / Medicine Science / 2019 / Cilt: 8 - Sayı: 3

Is TTF-1 a prognostic marker in non-small cell lung adenokarsinoma?

Pages
601–605
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When the patients without adenocarcinoma histology, unknown TTF-1 status, and lost follow-up were excluded, the remaining total number of 104 patient’s characteristics, chemotherapy types, treatment responses (as accommodation with Response Evaluation Criteria in Solid Tumors), progression-free survival (PFS) and overall survival (OS) were recorded and analyzed.TTF-1 positivity is significantly correlated with the female gender.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Thyroid transcription factor-1 (TTF-1) is first found to be a promoter of the thyroglobulin.
📊
Key Findings & Data:The primary function of this protein is the regulation of nuclear transcription.TTF-1 has suggested having both oncogenic and anti-oncogenic effects on tumor biology.
💡
Conclusion & Impact:When the patients without adenocarcinoma histology, unknown TTF-1 status, and lost follow-up were excluded, the remaining total number of 104 patient’s characteristics, chemotherapy types, treatment responses (as accommodation with Response Evaluation Criteria in Solid Tumors), progression-free survival (PFS) and overall survival (OS) were recorded and analyzed.TTF-1 positivity is significantly correlated with the female gender.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Thyroid transcription factor-1 (TTF-1) is first found to be a promoter of the thyroglobulin. The primary function of this protein is the regulation of nuclear transcription.TTF-1 has suggested having both oncogenic and anti-oncogenic effects on tumor biology. A total number of 1104 patient’s data with lung cancers are evaluated. When the patients without adenocarcinoma histology, unknown TTF-1 status, and lost follow-up were excluded, the remaining total number of 104 patient’s characteristics, chemotherapy types, treatment responses (as accommodation with Response Evaluation Criteria in Solid Tumors), progression-free survival (PFS) and overall survival (OS) were recorded and analyzed.TTF-1 positivity is significantly correlated with the female gender. The biopsy location among the groups was statistically different between the TTF-1 positive and negative groups. The EGFR mutation rate was significantly higher in the TTF-1 positive group. In the survival analysis, the TTF-1 positive patients have a significantly better OS in all study population. The statistically significant survival advantage was going on in the TTF-1 positive group when the TKI treated patients excluded. The PFS was not significantly different between the two groups. However, when the TKI treated patients excluded in both groups; the TTF-1 positive group had a significantly better PFS. In conclusion, TTF-1 positivity may be used as a positive prognostic marker for lung adenocarcinoma independent from TKI usage because of strongly correlated with a better OS.

🔖

Cite This Article

ARAZ, M., DEMİR, H., BEYPİNAR, I. (2019). Is TTF-1 a prognostic marker in non-small cell lung adenokarsinoma?. Medicine Science, Cilt: 8 - Sayı: 3, 601–605. https://ajindex.com/articles/276981

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Civitareale D, Lonigro R, Sinclair AJ, et al. A thyroid-specific nuclear protein essential for tissue-specific expression of the thyroglobulin promoter. EMBO J. 1989;8:2537-42
  2. Kimura S, Hara Y, Pineau T, et al. The T/ebp null mouse: Thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 1996;10:60-9
  3. Lazzaro D, Price M, Felice D, et al. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the fetal brain. Development. 1991;113:1093-104
  4. Minoo P, Hamdan H, Bu D, et al. TTF-1 regulates lung epithelial morphogenesis. Dev Biol.1995;172:694-8
  5. Alam MN, Berhane K, Boggaram V. Lung surfactant protein B promoter function is dependent on the helical phasing, orientation and combinatorial actions of cis-DNA elements. Gene. 2002;282:103-11
  6. Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol. 2001;116:319-25
  7. Ordóñez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Advances in Anatomic Pathology. 2000;7:123-7
  8. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-85
  9. Kendall J, Liu Q, Bakleh A, et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci. 2007;104:16663-8
  10. Kwei KA, Kim YH, Girard L, et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene. 2008;27:3635-40
  11. Tanaka H, Yanagisawa K, Shinjo K, et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 2007;67:6007–11
  12. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450:893-8
  13. Saito R-A, Watabe T, Horiguchi K, et al. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Cancer Res. 2009;69:2783-91
  14. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nature